Symbols / HEPA $0.05 -3.77% Hepion Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • OQB
HEPA Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country OQB · United States
Market Cap 1.49M
Enterprise Value 584.91K
Income -2.98M
Sales —
FCF (ttm) -227.41K
Book/sh 0.01
Cash/sh 0.09
Employees 2
Insider 10d —
IPO Feb 10, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.04
Forward P/E -0.00
PEG —
P/S —
P/B 3.64
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 3.54
Current Ratio 3.68
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 1.20
EPS next Y -11.43
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2024-04-16
Earnings (prior) 2024-04-16
ROA -45.42%
ROE -103.70%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 29.12M
Shs Float 21.62M
Insider Own 38.64%
Instit Own 0.02%
Short Float 4.10%
Short Ratio 0.05
Short Interest 448.18K
52W High 0.25
vs 52W High -79.60%
52W Low 0.03
vs 52W Low 54.55%
Beta 1.66
Impl. Vol. —
Rel Volume 0.18
Avg Volume 22.01K
Volume 3.97K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.05
Price $0.05
Change -3.77%
About

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.05
Latest analyst target
3. DCF / Fair value
$-0.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.05
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-12-07 down Brookline Capital Buy → Hold —
News
RSS: Latest HEPA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 STETZ GARY S Chief Executive Officer — 1,250,000 $0.04 $50,000
2026-04-21 PURCELL MICHAEL J. Director — 1,250,000 $0.04 $50,000
2026-04-21 APPAJOSYULA SIREESH Director — 1,250,000 $0.04 $50,000
2026-04-21 LOPRIORE VINCENT S Officer, Director and Beneficial Owner — 6,250,000 $0.04 $250,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
3.76
-80.56%
19.35
-57.25%
45.26
+3.76%
43.62
Research And Development
0.45
-96.24%
11.85
-66.76%
35.64
+7.12%
33.27
Selling General And Administration
3.32
-55.79%
7.50
-22.03%
9.62
-7.06%
10.35
General And Administrative Expense
3.32
-55.79%
7.50
-22.03%
9.62
-7.06%
10.35
Other Gand A
3.32
-55.79%
7.50
-22.03%
9.62
-7.06%
10.35
Total Expenses
3.76
-80.56%
19.35
-57.25%
45.26
+3.76%
43.62
Operating Income
-3.76
+80.56%
-19.35
+57.25%
-45.26
-3.76%
-43.62
Total Operating Income As Reported
-4.16
+78.48%
-19.35
+60.07%
-48.45
-6.51%
-45.49
EBITDA
-8.25
+44.55%
-14.88
+69.78%
-49.26
-9.47%
-45.00
Normalized EBITDA
-3.76
+80.53%
-19.32
+57.26%
-45.19
-3.79%
-43.54
Reconciled Depreciation
0.00
-100.00%
0.03
-54.18%
0.07
-13.34%
0.08
EBIT
-8.25
+44.66%
-14.91
+69.76%
-49.33
-9.43%
-45.07
Total Unusual Items
-4.49
-201.36%
4.43
+208.96%
-4.07
-179.38%
-1.46
Total Unusual Items Excluding Goodwill
-4.49
-201.36%
4.43
+208.96%
-4.07
-179.38%
-1.46
Special Income Charges
-0.40
+87.28%
-3.17
+0.72%
-3.19
-70.50%
-1.87
Other Special Charges
—
2.57
—
—
Impairment Of Capital Assets
0.40
0.00
-100.00%
3.19
+70.50%
1.87
Write Off
0.00
-100.00%
0.60
0.00
—
Net Income
-8.28
+37.25%
-13.19
+73.04%
-48.93
-15.94%
-42.20
Pretax Income
-8.28
+48.78%
-16.16
+67.24%
-49.34
-9.43%
-45.08
Net Non Operating Interest Income Expense
-0.02
+98.04%
-1.25
-13078.16%
-0.01
+6.88%
-0.01
Interest Expense Non Operating
0.02
-98.04%
1.25
+13078.16%
0.01
-6.88%
0.01
Net Interest Income
-0.02
+98.04%
-1.25
-13078.16%
-0.01
+6.88%
-0.01
Interest Expense
0.02
-98.04%
1.25
+13078.16%
0.01
-6.88%
0.01
Other Income Expense
-4.49
-201.36%
4.43
+208.96%
-4.07
-179.38%
-1.46
Gain On Sale Of Security
-4.09
-153.82%
7.60
+965.87%
-0.88
-311.48%
0.41
Tax Provision
0.00
+100.00%
-2.97
-625.94%
-0.41
+85.82%
-2.88
Tax Rate For Calcs
0.00
-100.00%
0.00
+2200.00%
0.00
-87.50%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.82
+2606.14%
-0.03
+65.08%
-0.09
Net Income Including Noncontrolling Interests
-8.28
+37.25%
-13.19
+73.04%
-48.93
-15.94%
-42.20
Net Income From Continuing Operation Net Minority Interest
-8.28
+37.25%
-13.19
+73.04%
-48.93
-15.94%
-42.20
Net Income From Continuing And Discontinued Operation
-8.28
+37.25%
-13.19
+73.04%
-48.93
-15.94%
-42.20
Net Income Continuous Operations
-8.28
+37.25%
-13.19
+73.04%
-48.93
-15.94%
-42.20
Normalized Income
-3.79
+77.48%
-16.81
+62.56%
-44.89
-9.93%
-40.84
Net Income Common Stockholders
-8.28
+37.25%
-13.19
+73.04%
-48.93
-7.92%
-45.34
Otherunder Preferred Stock Dividend
—
—
0.00
-100.00%
3.14
Diluted EPS
-0.88
+99.18%
-107.35
+82.58%
-616.07
-3.54%
-595.00
Basic EPS
-0.88
+99.18%
-107.35
+82.58%
-616.07
-3.54%
-595.00
Basic Average Shares
9.41
+7556.50%
0.12
+54.75%
0.08
+4.18%
0.08
Diluted Average Shares
9.41
+7556.50%
0.12
+54.75%
0.08
+4.18%
0.08
Diluted NI Availto Com Stockholders
-8.28
+37.25%
-13.19
+73.04%
-48.93
-7.92%
-45.34
Preferred Stock Dividends
—
—
—
3.14
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
3.07
+90.24%
1.61
-91.08%
18.09
-69.97%
60.24
Current Assets
3.07
+90.24%
1.61
-90.77%
17.49
-69.05%
56.50
Cash Cash Equivalents And Short Term Investments
1.83
+349.81%
0.41
-97.25%
14.79
-71.12%
51.19
Cash And Cash Equivalents
1.83
+349.81%
0.41
-97.25%
14.79
-71.12%
51.19
Cash Financial
1.83
+349.81%
0.41
-97.25%
14.79
-71.12%
51.19
Prepaid Assets
1.24
+2.86%
1.21
-55.32%
2.70
-49.09%
5.31
Total Non Current Assets
0.00
0.00
-100.00%
0.61
-83.82%
3.75
Net PPE
—
-0.00
-100.00%
0.24
-92.70%
3.32
Gross PPE
—
0.42
-32.34%
0.62
-82.87%
3.63
Accumulated Depreciation
—
-0.42
-10.87%
-0.38
-23.63%
-0.31
Properties
—
—
0.00
0.00
Buildings And Improvements
—
—
0.21
-93.43%
3.24
Machinery Furniture Equipment
—
0.06
+0.00%
0.06
+0.00%
0.06
Other Properties
—
0.36
-35.93%
0.56
+71.47%
0.33
Goodwill And Other Intangible Assets
—
—
0.00
-100.00%
3.19
Goodwill
—
—
—
0.00
Other Intangible Assets
—
—
—
3.19
Other Non Current Assets
—
—
0.36
-14.54%
0.43
Total Liabilities Net Minority Interest
0.40
-88.43%
3.48
-67.85%
10.81
+4.09%
10.39
Current Liabilities
0.30
-90.48%
3.14
-40.57%
5.29
-32.92%
7.89
Payables And Accrued Expenses
0.25
+0.59%
0.24
-94.91%
4.79
-13.87%
5.56
Payables
0.17
-23.79%
0.22
-90.63%
2.35
-11.89%
2.67
Accounts Payable
0.17
-23.79%
0.22
-90.63%
2.35
-11.89%
2.67
Current Accrued Expenses
0.08
+227.25%
0.02
-99.03%
2.44
-15.70%
2.89
Pensionand Other Post Retirement Benefit Plans Current
—
—
0.00
-100.00%
1.91
Total Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
0.05
-98.14%
2.90
+2401.81%
0.12
+116.20%
0.05
Current Debt
0.05
-98.14%
2.90
—
—
Current Capital Lease Obligation
—
0.00
-100.00%
0.12
+116.20%
0.05
Other Current Liabilities
—
—
0.39
+5.40%
0.37
Total Non Current Liabilities Net Minority Interest
0.10
-69.08%
0.33
-93.97%
5.52
+120.69%
2.50
Long Term Debt And Capital Lease Obligation
—
0.00
-100.00%
0.09
0.00
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.09
0.00
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.41
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
0.41
Other Non Current Liabilities
—
—
1.63
-21.96%
2.09
Stockholders Equity
2.67
+243.16%
-1.86
-125.59%
7.28
-85.40%
49.86
Common Stock Equity
0.97
+127.33%
-3.56
-163.71%
5.59
-88.40%
48.16
Capital Stock
1.70
+0.07%
1.70
+0.00%
1.70
-0.08%
1.70
Common Stock
0.00
+8200.00%
0.00
+40.00%
0.00
-97.38%
0.00
Preferred Stock
1.70
+0.00%
1.70
+0.00%
1.70
-0.06%
1.70
Share Issued
11.62
+8249.85%
0.14
+44.40%
0.10
+26.43%
0.08
Ordinary Shares Number
11.62
+8249.85%
0.14
+44.40%
0.10
+26.43%
0.08
Additional Paid In Capital
247.06
+5.47%
234.25
+1.72%
230.29
+2.83%
223.95
Retained Earnings
-246.10
-3.48%
-237.82
-5.87%
-224.63
-27.85%
-175.70
Gains Losses Not Affecting Retained Earnings
0.01
+0.00%
0.01
+110.59%
-0.08
+12.63%
-0.09
Other Equity Adjustments
0.01
+0.00%
0.01
+110.59%
-0.08
+12.63%
-0.09
Total Equity Gross Minority Interest
2.67
+243.16%
-1.86
-125.59%
7.28
-85.40%
49.86
Total Capitalization
2.67
+243.16%
-1.86
-125.59%
7.28
-85.40%
49.86
Working Capital
2.77
+281.07%
-1.53
-112.54%
12.20
-74.91%
48.61
Invested Capital
1.03
+255.89%
-0.66
-111.79%
5.59
-88.40%
48.16
Total Debt
0.05
-98.14%
2.90
+1287.43%
0.21
+289.86%
0.05
Net Debt
—
2.49
—
—
Capital Lease Obligations
—
0.00
-100.00%
0.21
+289.86%
0.05
Net Tangible Assets
2.67
+243.16%
-1.86
-125.59%
7.28
-85.40%
49.86
Tangible Book Value
0.97
+127.33%
-3.56
-163.71%
5.59
-88.40%
48.16
Current Notes Payable
0.05
-98.14%
2.90
0.00
—
Derivative Product Liabilities
0.10
-69.08%
0.33
-91.22%
3.80
0.00
Preferred Shares Number
0.09
+0.00%
0.09
+0.00%
0.09
-0.13%
0.09
Preferred Stock Equity
1.70
+0.00%
1.70
+0.00%
1.70
-0.06%
1.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-3.27
+82.04%
-18.22
+55.45%
-40.89
-16.96%
-34.96
Cash Flow From Continuing Operating Activities
-3.27
+82.04%
-18.22
+55.45%
-40.89
-16.96%
-34.96
Net Income From Continuing Operations
-8.28
+37.25%
-13.19
+73.04%
-48.93
-15.94%
-42.20
Depreciation Amortization Depletion
0.00
-100.00%
0.03
-54.18%
0.07
-13.34%
0.08
Depreciation
0.00
-100.00%
0.03
-54.18%
0.07
—
Depreciation And Amortization
0.00
-100.00%
0.03
-54.18%
0.07
-13.34%
0.08
Other Non Cash Items
—
1.82
+512.70%
-0.44
-6.03%
-0.41
Stock Based Compensation
0.02
-97.37%
0.79
-40.94%
1.34
-47.50%
2.55
Asset Impairment Charge
0.40
-32.88%
0.60
-81.19%
3.19
+70.50%
1.87
Deferred Tax
—
0.00
+100.00%
-0.41
0.00
Deferred Income Tax
—
0.00
+100.00%
-0.41
0.00
Operating Gains Losses
4.09
+173.30%
-5.58
-523.43%
1.32
—
Gain Loss On Investment Securities
4.09
+173.30%
-5.58
-523.43%
1.32
—
Change In Working Capital
0.49
+118.38%
-2.68
-190.30%
2.97
-5.76%
3.15
Change In Prepaid Assets
0.49
-73.55%
1.86
-30.51%
2.68
+191.62%
0.92
Change In Payables And Accrued Expense
0.00
+100.03%
-4.55
-1600.59%
0.30
-86.51%
2.25
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
0.00
-100.00%
0.21
+136.99%
0.09
-64.51%
0.25
Change In Other Current Liabilities
0.00
+100.00%
-0.21
-116.13%
-0.10
+63.28%
-0.26
Investing Cash Flow
-0.13
+77.98%
-0.60
-4094.63%
-0.01
-1.66%
-0.01
Cash Flow From Continuing Investing Activities
-0.13
+77.98%
-0.60
-4094.63%
-0.01
-1.66%
-0.01
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.01
-1.66%
-0.01
Purchase Of PPE
—
0.00
+100.00%
-0.01
+12.44%
-0.02
Sale Of PPE
—
—
0.00
-100.00%
0.00
Capital Expenditure
—
—
-0.01
+12.44%
-0.02
Net Investment Purchase And Sale
-0.13
0.00
—
—
Purchase Of Investment
-0.13
0.00
—
—
Net Other Investing Changes
—
-0.60
—
—
Financing Cash Flow
4.83
+10.93%
4.35
-3.23%
4.49
+187.49%
-5.14
Cash Flow From Continuing Financing Activities
4.83
+10.93%
4.35
-3.23%
4.49
+187.49%
-5.14
Net Issuance Payments Of Debt
-3.37
0.00
—
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-3.37
0.00
—
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-3.37
0.00
—
0.00
Net Long Term Debt Issuance
-3.37
0.00
—
0.00
Net Common Stock Issuance
0.00
-100.00%
2.50
0.00
0.00
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-21.00
Proceeds From Stock Option Exercised
9.00
+386.56%
1.85
-58.85%
4.49
0.00
Net Other Financing Charges
-0.80
—
—
-2.00
Changes In Cash
1.42
+109.83%
-14.47
+60.27%
-36.41
+9.24%
-40.11
Effect Of Exchange Rate Changes
0.00
-100.00%
0.09
+1634.16%
0.01
+110.66%
-0.05
Beginning Cash Position
0.41
-97.25%
14.79
-71.12%
51.19
-43.96%
91.35
End Cash Position
1.83
+349.81%
0.41
-97.25%
14.79
-71.12%
51.19
Free Cash Flow
-3.27
+82.04%
-18.22
+55.46%
-40.90
-16.94%
-34.98
Interest Paid Supplemental Data
0.02
0.00
0.00
-100.00%
0.00
Common Stock Issuance
0.00
-100.00%
2.50
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
2.50
0.00
-100.00%
17.86
Net Preferred Stock Issuance
—
—
0.00
+100.00%
-3.14
Preferred Stock Issuance
—
—
0.00
-100.00%
17.86
Preferred Stock Payments
—
—
0.00
+100.00%
-21.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category